US FDA warns of harmful reactions to fake Botox injections
BOSTON, April 10 (Reuters) - The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals (REGN.O), opens new tab of manipulating Medicare's drug-pricing process by inflating the average sales price for its expensive macular degeneration drug Eylea.
Bayer Pharmaceuticals advances next generation of blockbuster medicines
Aflibercept 8 mg clinical study data now published in The Lancet
EYLEA Injection 8 mg Pivotal Data in wAMD and DME Published in The Lancet
Regeneron touts `favorable` physician reports on Eylea HD
New Eylea™ 8 mg approved in Japan
New Eylea™ 8 mg approved in EU
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...
Regeneron Gains After Eye-Drug Patent Victory Over Viatris